Real-world efficacy and safety of peptide receptor radionuclide therapy (PRRT) in gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

被引：0

作者：

Abou Jokh Casas, Estephany ^{[1
]}

Martinez, Nieves Purificacion ^{[2
]}

Herranz, Urbano Anido ^{[3
]}

Cabezas Agricola, Jose Manuel ^{[4
]}

Ferreiro, Silvia Varela ^{[5
]}

Maseda, Alberto Carral ^{[5
]}

Calvo, Ovidio Fernandez ^{[6
]}

Mato Mato, Jose Antonio ^{[7
]}

Seoane, Zulema Nogareda ^{[8
]}

Martinez de LLano, Sofia Rodriguez ^{[9
]}

Varela, Maria Quindos ^{[10
]}

Baron, Francisco ^{[11
]}

Fonseca, Omar Rodriguez ^{[8
]}

Castineira, Antia Cousillas ^{[12
]}

Garcia, Gloria Muniz ^{[13
]}

De Matias Leralta, Jose Maria ^{[14
]}

Catalina, Pablo Fernandez ^{[15
]}

Cameselle Teijeiro, Jose Manuel ^{[16
]}

Bernardez, Beatriz ^{[17
]}

Nunez, Virginia Pubul ^{[18
]}

机构：

[1] Hosp Clin Univ Santiago de Compostela, Dept Nucl Med, Santiago De Compostela, Spain

[2] Hosp Univ A Coruna, Coruna, Spain

[3] Hosp Clin Univ, Santiago De Compostela, Spain

[4] Hosp Clin Univ Santiago de Compostela, Dept Endocrinol, Santiago De Compostela, Spain

[5] Hosp Univ Lucus Augusti, Dept Med Oncol, Lugo, Spain

[6] Complejo Hosp Univ Ourense, Dept Med Oncol, Orense, Spain

[7] Complejo Hosp Univ Ourense, Dept Endocrinol, Orense, Spain

[8] Hosp Univ Lucus Augusti, Dept Nucl Med, Lugo, Spain

[9] Ctr Oncol Galicia, Dept Nucl Med, La Coruna, Spain

[10] Univ Hosp A Coruna CHUAC SERGAS, Dept Med Oncol, La Coruna, Spain

[11] Univ Hosp A Coruna, Dept Med Oncol, La Coruna, Spain

[12] Complejo Hosp Pontevedra, Dept Med Oncol, Pontevedra, Spain

[13] Complexo Hosp Univ Ourense, Dept Nucl Med, Orense, Spain

[14] Hosp Univ Lucus Augusti, Dept Endocrinol, Lugo, Spain

[15] Complexo Hosp Univ Pontevedra, Dept Endocrinol, Pontevedra, Spain

[16] Hosp Clin Univ Santiago de Compostela, Dept Pathol, Santiago De Compostela, Spain

[17] Hlth Res Inst Santiago de Com, Clin Pharmacol Grp, Hosp Clin Santiago SERGAS, Dept Pharm, Santiago De Compostela, Spain

[18] Hosp Clin Univ Santiago de Compostela, Dept Nucl Med, Santiago De Compostela, Spain

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 03期

关键词：

D O I：

10.1200/JCO.2021.39.3_suppl.364

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

364

引用

页数：2

共 50 条

[1] Surgery after Peptide Receptor Radionuclide Therapy (PRRT) in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Bertani, E.
Chiappa, A.
Fazio, N.
Grana, C.
Bodei, L.
Falconi, M.
Ravizza, D.
Spada, F.
Andreoni, B.
[J]. NEUROENDOCRINOLOGY, 2014, 99 (3-4) : 285 - 285
[2] The role of systemic inflammatory factors in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with peptide receptor radionuclide therapy (PRRT).
Abou Jokh Casas, Estephany
Lago, Nieves Martinez
Cabezas Agricola, Jose Manuel
Herranz, Urbano Anido
Baron, Francisco
Calvo, Ovidio Fernandez
Varela, Maria Quindos
Ferreiro, Silvia Varela
Maseda, Alberto Carral
De Matias Leralta, Jose Maria
Seoane, Zulema Nogareda
Castineira, Antia Cousillas
Martinez de LLano, Sofia Rodriguez
Mato Mato, Jose Antonio
Catalina, Pablo Fernandez
Fonseca, Omar Rodriguez
Garcia, Gloria Muniz
Bernardez, Beatriz
Cameselle Teijeiro, Jose Manuel
Nunez, Virginia Pubul
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[3] Peptide receptor radionuclide therapy (PRRT) for GEP-NETs
Bergsma, Hendrik
van Vliet, Esther I.
Teunissen, Jaap J. M.
Kam, Boen L. R.
de Herder, Wouter W.
Peeters, Robin P.
Krenning, Eric P.
Kwekkeboom, Dik J.
[J]. BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2012, 26 (06) : 867 - 881
[4] Peptide receptor radionuclide therapy of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): From literature to practice
Bournaud, C.
Kelly, A.
Hindie, E.
Tenenbaum, F.
Faivre-Chauvet, A.
Courbon, F.
Taieb, D.
Dierickx, L. O.
Coriat, R.
Ansquer, C.
[J]. MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE, 2017, 41 (01): : 42 - 54
[5] Can tumor absorbed dose predict response to Peptide Receptor Radionuclide Therapy (PRRT) in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs)?
Mileva, M.
Marin, G.
Levillain, H.
van Bogaert, C.
Critchi, G.
Marin, C.
Flamen, P.
Karfis, I
[J]. JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 : 153 - 153
[6] Utility of Midpoint Imaging in Patients Receiving Peptide Receptor Radionuclide Therapy (PRRT) for Advance Progressive Gastroenteropancreatic-Neuroendocrine Tumors (GEP-NETs)
Norman, Aurora P.
Wee, Christopher
Hobday, Timothy J.
Kendi, Ayse T.
Johnson, Geoffrey B.
Thorpe, Matthew P.
Lunn, Brendan W.
Bach, Corrie R.
Halfdanarson, Thorvardur R.
[J]. PANCREAS, 2022, 51 (03) : E45 - E45
[7] Role of systemic inflammatory factors in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with peptide receptor radionuclide therapy (PRRT): From biology to theragnosis
Casas, E. Abou-Jokh
Martinez-Lagob, N.
Araujo, M. C. Mallon
Agricolac, J. M. Cabezas
Seoaned, Z. Nogareda
Castineirae, A. Cousillas
Morellf, A. Ruibal
Nuneza, V. Pubul
[J]. REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2023, 42 (03): : 156 - 162
[8] Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Kizilgul, Muhammed
Delibasi, Tuncay
[J]. TRANSLATIONAL GASTROINTESTINAL CANCER, 2015, 4 (01) : 39 - 56
[9] Real-world efficacy and safety of peptide receptor radionuclide therapy (PRRT) with 177Lu-Dotatate (Lutathera) (LU) in neuroendocrine tumors (NETs)
Navarro Martin, M.
Teran Brage, E.
Campana-Diaz, E.
Garcia-Talavera, P.
Reguera Puertas, P.
Rama-Alonso, S.
Garijo-Martinez, M. C.
Felix, L. C.
Diaz Sanchez, P.
Vidal Tocino, R.
Fonseca Sanchez, E.
[J]. ANNALS OF ONCOLOGY, 2024, 35 : S95 - S95
[10] Efficacy of the Chronic Lanreotide Treatment of Gastroenteropancreatic Neuroendocrine Tumors (GEP/NET) after Peptide Receptor Radionuclide Therapy (PRRT)
Szalus, N.
Kaminski, G.
Podgajny, Z.
Dziuk, E.
[J]. NEUROENDOCRINOLOGY, 2009, 90 (01) : 137 - 137

← 1 2 3 4 5 →